Every S-3 that Nanoviricides (NNVC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow NNVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NNVC filings page.
NanoViricides, Inc. (NNVC) has filed a Form S-3 registering for resale up to 2,516,339 shares of common stock issuable upon exercise of outstanding Common Stock Purchase Warrants held by a selling stockholder. The warrants have an exercise price of $1.75 per share and were issued in a July 24, 2026 registered direct offering.
NanoViricides is not selling any shares in this transaction and will receive no proceeds from resales by the selling stockholder. The company would receive up to approximately $4.4 million in gross proceeds only if all such warrants are exercised for cash.
Common shares outstanding were 25,527,353 as of August 21, 2026, rising to 28,043,692 assuming full exercise of these warrants. NanoViricides is a clinical-stage antiviral developer with no revenues to date, and its most recent audited financial statements include an auditor’s explanatory paragraph about substantial doubt regarding its ability to continue as a going concern.
NanoViricides, Inc. files a Form S-3 to register for resale up to 1,333,334 shares of Common Stock issuable upon exercise of Common Stock Purchase Warrants issued in a registered direct offering.
The prospectus states the Company will not receive proceeds from resales by the selling stockholder but would receive approximately $2.33 million in gross proceeds if the Common Warrants are exercised in full at an exercise price of $1.75 per share. Shares outstanding were 22,982,816 as of June 15, 2026, and the post-offering share count assumes full exercise would be 24,316,150.
NanoViricides, Inc. filed a shelf registration on Form S-3 to offer up to $50,000,000 of various securities, including common stock, preferred stock, debt, warrants, rights and units, with specific terms to be set in prospectus supplements.
The prospectus states 22,982,816 shares of Common Stock outstanding as of June 4, 2026, 918,422 shares of Series A Preferred outstanding, and an aggregate market value of Common Stock held by non-affiliates of approximately $35,500,000 based on a $1.59 closing price on June 2, 2026.
NanoViricides, Inc. is registering up to 7,142,858 shares of common stock for resale by a selling stockholder, representing shares underlying Series A and Series B common stock purchase warrants.
The warrants, issued in a November 10, 2025 private placement, are exercisable at $1.75 and $2.00 per share and, if fully exercised for cash, could provide the company with approximately $13.4 million in gross proceeds, though the company will not receive any proceeds from resale of the shares themselves. The sole selling stockholder, Armistice Capital Master Fund, Ltd., beneficially owns 10,714,287 shares and is subject to a 4.99% beneficial ownership limitation on warrant exercises. As of November 10, 2025, NanoViricides had 21,568,429 common shares outstanding, and its most recent audited financial statements include an explanatory paragraph noting substantial doubt about the company's ability to continue as a going concern.